Skip to main content
. Author manuscript; available in PMC: 2020 May 15.
Published in final edited form as: Cancer Res. 2019 Apr 2;79(10):2536–2548. doi: 10.1158/0008-5472.CAN-18-2170

Figure 3. TMZ modulates binding of p53 and NF-кB to кB and p53 binding sites.

Figure 3.

(A) Schematic representation of the кB and p53 binding sites in human MALAT1. (B) EMSA using the кB and p53 probes with increasing concentrations of purified His-p50 or p53 (0 - 300 ng). (C) EMSA using nuclear extracts from U87 cells treated with vehicle or TMZ (100 μM TMZ, 16 hours). Supershift (SS) with anti-p50 and anti-p53. Oct1 EMSA demonstrates equal lysate loading. (D) qChIP using primers spanning the кB and p53 BSs in U87 cells treated as shown (100 μM TMZ, 16 hours). Data represent chromatin enrichment of the indicated protein, relative to input DNA after controlling for non-specific binding using anti-histone H1 (positive control) and anti-IgG, normalized to vehicle, mean ±SD of triplicate samples shown. *, p< 0.05.